IAP
GANX icon

Indie Asset Partners’s Gain Therapeutics GANX Stock Holding History

Indie Asset Partners’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29,652
Closed -$221K – 129
2021
Q3 		$221K Buy
+29,652
New +$248K 0.18% 112

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Indie Asset Partners's GANX Position: Q4 2021 in Review

Indie Asset Partners sold out of Gain Therapeutics (GANX) in Q4 2021, closing a stake of 29,652 shares — an estimated $221K sold.

Indie Asset Partners first reported a position in GANX in Q3 2021 and held it in 1 quarter. The position peaked at $221K in Q3 2021. 19 funds tracked by Wall St. Rank hold GANX as of Q4 2021.

  • Indie Asset Partners reported no remaining Gain Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Indie Asset Partners sold 29,652 Gain Therapeutics shares in Q4 2021, an estimated $221K.
  • Indie Asset Partners first reported a position in Gain Therapeutics in Q3 2021 and held it in 1 quarter.
  • Indie Asset Partners's Gain Therapeutics position peaked at $221K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2021.

Based on Indie Asset Partners's 13F filing for Q4 2021, filed 11 Feb 2022.